U.S. Professional Services Stock News

IQVIA Holdings has launched IQVIA.ai, a unified AI platform built with Nvidia technology for the life sciences sector. The platform is designed to combine healthcare grade AI, data and compliance for pharmaceutical and healthcare clients. Early adoption is reported among several top global pharmaceutical companies, with further expansion of the platform planned. For investors watching NYSE:IQV, the launch of IQVIA.ai arrives at a time when the stock trades around $170.72 and recent returns...

If you are wondering whether Microchip Technology is still attractively priced after its recent run, this breakdown will help you understand what the current share price implies. The stock closed at US$67.22, with returns of 11.9% over the past week, 3.8% over the past month, 3.4% year to date, and 81.8% over the last year, set against 3-year and 5-year returns of a 10.1% decline and a 6.0% decline. Recent coverage has focused on Microchip Technology as part of the wider interest in...

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Potential Satellogic Inc. ( NASDAQ:SATL ) shareholders may wish to note that the Chief Financial Officer, Richard Dunn...

Some of the losses seen by insiders who purchased US$148.8k worth of PowerFleet, Inc. ( NASDAQ:AIOT ) shares over the...

Some Argan, Inc. ( NYSE:AGX ) shareholders may be a little concerned to see that the Independent Director, John...

We feel now is a pretty good time to analyse Orion Energy Systems, Inc.'s ( NASDAQ:OESX ) business as it appears the...

Investors may be wondering whether Amcor's current share price reflects its true worth, or if the market is missing something important about this packaging company. Over the last week the stock is up 4.5%, although the return over 30 days is an 8.0% decline and the 1-year return sits at a 5.4% loss, which may have shifted how some investors view its risk and potential. These mixed returns have kept attention on how the market is reacting to Amcor and how sentiment can change quickly when...

Wondering whether Workiva is starting to look attractively priced or still too expensive at around US$59.77 per share? This article breaks down what that price could imply about value. The stock is up 1.8% over the last 7 days, while the 1 year return sits at a 9.4% loss and the year to date return is a 28.0% loss, with a 30 day return of a 7.9% loss. Recent coverage around Workiva has focused on how the share price performance contrasts with its longer term track record, which includes a...

If you are wondering whether Occidental Petroleum at around US$62.96 offers value or is primarily driven by sentiment, this article walks through the numbers so you can assess the price tag with more confidence. The stock recently saw a 5.0% decline over the last 7 days, alongside a 16.2% gain over 30 days and returns of 48.6% year to date and 66.0% over 1 year. Recent attention on Occidental Petroleum has focused on its role in the US energy sector and how investors interpret its exposure...

If you are wondering whether Astrana Health at around US$26 is offering good value or fresh risk, it helps to compare the share price with what the underlying business might be worth. The stock has recently moved, with returns of 6.8% over the last 7 days and 4.4% over the past month, while the 1 year return sits at an 11.2% decline and the 3 year return at a 33.2% decline. This can change how the market views both its potential and its risks. These moves come as investors continue to assess...

Radian Group (NYSE:RDN) has agreed to acquire specialty insurer and reinsurer Inigo, expanding beyond its core mortgage insurance business. The deal adds specialty P&C and reinsurance exposure to Radian's portfolio, reshaping the company's overall business mix. This transaction marks a meaningful shift in Radian's long term risk profile and revenue sources away from exclusive reliance on the US housing market. For investors watching Radian Group at a share price of $33.97, this move arrives...

This article explores whether Liberty Energy's share price still reflects good value, or if the easier gains may already have occurred, by considering what the current price might be implying about the company. Liberty Energy closed at US$27.67, with a 4.1% decline over the last 7 days, a 3.2% gain over 30 days, a 46.6% return year to date, and a 169.7% return over the past year. Recent coverage has focused on Liberty Energy as part of broader discussions around US energy services companies...

Worthington Steel (WS) is back in focus after reporting third quarter results that showed higher sales but lower quarterly net income compared with a year earlier, along with higher nine-month earnings and a reaffirmed quarterly dividend. See our latest analysis for Worthington Steel. The latest results and dividend decision come after a mixed price pattern, with a 5.05% 7 day share price return, a 19.61% 30 day share price decline, and a 31.76% 1 year total shareholder return, suggesting...

AI is starting to reshape how healthcare is delivered, from spotting disease earlier to tailoring treatments and cutting wasted time in hospitals, just as energy driven inflation and higher yields keep pressure on costs worldwide. For investors, that mix of structural healthcare demand and AI driven efficiency tools offers exposure to a theme that is less tied to short term swings in consumer spending or manufacturing cycles. This article walks through 3 stocks from our Transformative AI...

Acuity (AYI) is back in focus after its second quarter 2026 earnings, where adjusted earnings per share came in ahead of expectations while revenue lagged forecasts, highlighting contrasting trends across its Lighting and Intelligent Spaces businesses. See our latest analysis for Acuity. The share price reaction has been mixed, with a 1 day share price return of 1.06% after earnings but a 90 day share price return representing a 28.55% decline. However, the 3 year total shareholder return of...

Olin Corporation recently received an upgrade from Wells Fargo, with the firm citing expectations of stronger margins in its electrochemical operations supported by higher caustic soda prices and stable North American natural gas costs. This shift in analyst view highlights how Olin’s earnings outlook is increasingly being tied to both its cost position and evolving global chemical pricing shaped by geopolitical tensions. We’ll now examine how this margin-focused upgrade from Wells Fargo...

In early April 2026, Prestige Consumer Healthcare faced pressure after regulatory scrutiny, including FTC concerns over industry consolidation and a federal healthcare fraud crackdown, weighed on sentiment around its over-the-counter product portfolio. Beyond the immediate regulatory overhang, the episode highlights how sector-wide oversight can quickly reshape market perceptions of risk around even established healthcare brands. Against this backdrop of intensified regulatory attention,...

Healthcare Services Group (HCSG) has been drawing attention after a strong 1 year total return of 85.35%, in contrast with recent share price softness over the past month and past 3 months. See our latest analysis for Healthcare Services Group. Recent trading has cooled after that strong 1 year total shareholder return of 85.35%. The 30 day share price return of an 11.14% decline points to fading near term momentum, even as the longer term total shareholder return profile remains positive...

Global Business Travel Group (GBTG) is back on investor radar after options activity showed elevated implied volatility in certain call contracts. This coincides with UBS reaffirming its rating while trimming expectations and the company maintaining its 2026 guidance. See our latest analysis for Global Business Travel Group. At a share price of US$5.56, Global Business Travel Group has seen short term momentum soften, with a 7 day share price return of 2.96% set against a 90 day share price...

Tarsus Pharmaceuticals has already dosed the first participant in its Phase 2 Calliope trial of TP-05, an oral lotilaner-based therapy being tested in about 700 at-risk adults across U.S. Lyme-endemic regions, where no FDA-approved drug prophylaxis currently exists. This move extends Tarsus beyond eye-care into infectious disease prevention, targeting a large U.S. population considered at moderate to high risk for Lyme disease. We’ll now examine how TP-05’s Phase 2 progress, as a potential...

Over the last 7 days, the United States market has risen by 3.5%, contributing to a remarkable 31% increase over the past year, with earnings forecasted to grow by 16% annually. In this thriving environment, identifying stocks that are potentially undervalued can offer investors opportunities to capitalize on price discrepancies relative to their intrinsic value.

The United States market has shown robust growth, rising 3.5% over the last week and 31% over the past year, with earnings expected to increase by 16% annually in the coming years. In such a thriving market, identifying stocks with strong financials becomes crucial for investors seeking both affordability and growth potential. Although often considered a term from bygone eras, penny stocks continue to offer intriguing opportunities within smaller or newer companies that might surprise...

The United States market has shown impressive strength, rising 3.5% over the last week and climbing 31% over the past year, with earnings projected to grow by 16% annually. In such a robust environment, identifying lesser-known stocks with strong fundamentals and growth potential can offer intriguing opportunities for investors seeking to diversify their portfolios.